RapamycinFungusV1, Main, Exploration, bibRecord, 000918

Attenuation of CD4+CD25+ Regulatory T Cells in the Tumor Microenvironment by Metformin, a Type 2 Diabetes Drug.

Identifieur interne : 000918 ( Main/Exploration ); précédent : 000917; suivant : 000919

Attenuation of CD4+CD25+ Regulatory T Cells in the Tumor Microenvironment by Metformin, a Type 2 Diabetes Drug.

Auteurs : Yuki Kunisada [Japon] ; Shingo Eikawa [Japon] ; Nahoko Tomonobu [Japon] ; Shohei Domae [Japon] ; Takenori Uehara [Japon] ; Shohei Hori [Japon] ; Yukihiro Furusawa [Japon] ; Koji Hase [Japon] ; Akira Sasaki [Japon] ; Heiichiro Udono [Japon]

Source :

EBioMedicine [ 2352-3964 ] ; 2017.

RBID : pubmed:29066174

Descripteurs français

KwdFr :
- Antigène CTLA-4 (génétique), Antigènes CD (génétique), Complexe-1 cible mécanistique de la rapamycine (antagonistes et inhibiteurs), Différenciation cellulaire (effets des médicaments et des substances chimiques), Facteurs de transcription Forkhead (génétique), Humains (MeSH), Interleukine-10 (génétique), Intégrines alpha (génétique), Lectines de type C (génétique), Lymphocytes T régulateurs (effets des médicaments et des substances chimiques), Lymphocytes T régulateurs (immunologie), Metformine (administration et posologie), Microenvironnement tumoral (effets des médicaments et des substances chimiques), Protein kinases (génétique), Régulation de l'expression des gènes (effets des médicaments et des substances chimiques), Sirolimus (administration et posologie), Transactivateurs (génétique), Transporteur de glucose de type 1 (génétique), Tumeurs (anatomopathologie), Tumeurs (génétique), Tumeurs (traitement médicamenteux).
MESH :
- administration et posologie : Metformine, Sirolimus.
- anatomopathologie : Tumeurs.
- antagonistes et inhibiteurs : Complexe-1 cible mécanistique de la rapamycine.
- effets des médicaments et des substances chimiques : Différenciation cellulaire, Lymphocytes T régulateurs, Microenvironnement tumoral, Régulation de l'expression des gènes.
- génétique : Antigène CTLA-4, Antigènes CD, Facteurs de transcription Forkhead, Interleukine-10, Intégrines alpha, Lectines de type C, Protein kinases, Transactivateurs, Transporteur de glucose de type 1, Tumeurs.
- immunologie : Lymphocytes T régulateurs.
- traitement médicamenteux : Tumeurs.
- Humains.

English descriptors

KwdEn :
- Antigens, CD (genetics), CTLA-4 Antigen (genetics), Cell Differentiation (drug effects), Forkhead Transcription Factors (genetics), Gene Expression Regulation (drug effects), Glucose Transporter Type 1 (genetics), Humans (MeSH), Integrin alpha Chains (genetics), Interleukin-10 (genetics), Lectins, C-Type (genetics), Mechanistic Target of Rapamycin Complex 1 (antagonists & inhibitors), Metformin (administration & dosage), Neoplasms (drug therapy), Neoplasms (genetics), Neoplasms (pathology), Protein Kinases (genetics), Sirolimus (administration & dosage), T-Lymphocytes, Regulatory (drug effects), T-Lymphocytes, Regulatory (immunology), Trans-Activators (genetics), Tumor Microenvironment (drug effects).
MESH :
- chemical , administration & dosage : Metformin, Sirolimus.
- chemical , antagonists & inhibitors : Mechanistic Target of Rapamycin Complex 1.
- chemical , genetics : Antigens, CD, CTLA-4 Antigen, Forkhead Transcription Factors, Glucose Transporter Type 1, Integrin alpha Chains, Interleukin-10, Lectins, C-Type, Protein Kinases, Trans-Activators.
- drug effects : Cell Differentiation, Gene Expression Regulation, T-Lymphocytes, Regulatory, Tumor Microenvironment.
- drug therapy : Neoplasms.
- genetics : Neoplasms.
- immunology : T-Lymphocytes, Regulatory.
- pathology : Neoplasms.
- Humans.

Abstract

CD4⁺CD25⁺ regulatory T cells (Treg), an essential subset for preventing autoimmune diseases, is implicated as a negative regulator in anti-tumor immunity. We found that metformin (Met) reduced tumor-infiltrating Treg (Ti-Treg), particularly the terminally-differentiated CD103⁺KLRG1⁺ population, and also decreased effector molecules such as CTLA4 and IL-10. Met inhibits the differentiation of naïve CD4⁺ T cells into inducible Treg (iTreg) by reducing forkhead box P3 (Foxp3) protein, caused by mTORC1 activation that was determined by the elevation of phosphorylated S6 (pS6), a downstream molecule of mTORC1. Rapamycin and compound C, an inhibitor of AMP-activated protein kinase (AMPK) restored the iTreg generation, further indicating the involvement of mTORC1 and AMPK. The metabolic profile of iTreg, increased Glut1-expression, and reduced mitochondrial membrane-potential and ROS production of Ti-Treg aided in identifying enhanced glycolysis upon Met-treatment. The negative impact of Met on Ti-Treg may help generation of the sustained antitumor immunity.

DOI: 10.1016/j.ebiom.2017.10.009
PubMed: 29066174
PubMed Central: PMC5704053

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000695
to stream Main, to step Curation: 000695

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Attenuation of CD4<sup>+</sup>
CD25<sup>+</sup>
 Regulatory T Cells in the Tumor Microenvironment by Metformin, a Type 2 Diabetes Drug.</title>
<author><name sortKey="Kunisada, Yuki" sort="Kunisada, Yuki" uniqKey="Kunisada Y" first="Yuki" last="Kunisada">Yuki Kunisada</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan; Department of Oral and Maxillofacial Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan; Department of Oral and Maxillofacial Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558</wicri:regionArea>
<wicri:noRegion>Okayama 700-8558</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Eikawa, Shingo" sort="Eikawa, Shingo" uniqKey="Eikawa S" first="Shingo" last="Eikawa">Shingo Eikawa</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558</wicri:regionArea>
<wicri:noRegion>Okayama 700-8558</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tomonobu, Nahoko" sort="Tomonobu, Nahoko" uniqKey="Tomonobu N" first="Nahoko" last="Tomonobu">Nahoko Tomonobu</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558</wicri:regionArea>
<wicri:noRegion>Okayama 700-8558</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Domae, Shohei" sort="Domae, Shohei" uniqKey="Domae S" first="Shohei" last="Domae">Shohei Domae</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Oral and Maxillofacial Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Oral and Maxillofacial Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558</wicri:regionArea>
<wicri:noRegion>Okayama 700-8558</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Uehara, Takenori" sort="Uehara, Takenori" uniqKey="Uehara T" first="Takenori" last="Uehara">Takenori Uehara</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan; Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan; Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558</wicri:regionArea>
<wicri:noRegion>Okayama 700-8558</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hori, Shohei" sort="Hori, Shohei" uniqKey="Hori S" first="Shohei" last="Hori">Shohei Hori</name>
<affiliation wicri:level="4"><nlm:affiliation>Laboratory of Immunology and Microbiology, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo 113-0033, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Laboratory of Immunology and Microbiology, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo 113-0033</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
<orgName type="university">Université de Tokyo</orgName>
<placeName><settlement type="city">Tokyo</settlement>
<region type="province">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Furusawa, Yukihiro" sort="Furusawa, Yukihiro" uniqKey="Furusawa Y" first="Yukihiro" last="Furusawa">Yukihiro Furusawa</name>
<affiliation wicri:level="3"><nlm:affiliation>Division of Biochemistry, Keio University Graduate School of Pharmaceutical Science, Tokyo, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Division of Biochemistry, Keio University Graduate School of Pharmaceutical Science, Tokyo</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hase, Koji" sort="Hase, Koji" uniqKey="Hase K" first="Koji" last="Hase">Koji Hase</name>
<affiliation wicri:level="3"><nlm:affiliation>Division of Biochemistry, Keio University Graduate School of Pharmaceutical Science, Tokyo, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Division of Biochemistry, Keio University Graduate School of Pharmaceutical Science, Tokyo</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sasaki, Akira" sort="Sasaki, Akira" uniqKey="Sasaki A" first="Akira" last="Sasaki">Akira Sasaki</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Oral and Maxillofacial Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Oral and Maxillofacial Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558</wicri:regionArea>
<wicri:noRegion>Okayama 700-8558</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Udono, Heiichiro" sort="Udono, Heiichiro" uniqKey="Udono H" first="Heiichiro" last="Udono">Heiichiro Udono</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan. Electronic address: udono@cc.okayama-u.ac.jpudono@cc.okayama-u.ac.jp.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558</wicri:regionArea>
<wicri:noRegion>Okayama 700-8558</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:29066174</idno>
<idno type="pmid">29066174</idno>
<idno type="doi">10.1016/j.ebiom.2017.10.009</idno>
<idno type="pmc">PMC5704053</idno>
<idno type="wicri:Area/Main/Corpus">000695</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000695</idno>
<idno type="wicri:Area/Main/Curation">000695</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000695</idno>
<idno type="wicri:Area/Main/Exploration">000695</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Attenuation of CD4<sup>+</sup>
CD25<sup>+</sup>
 Regulatory T Cells in the Tumor Microenvironment by Metformin, a Type 2 Diabetes Drug.</title>
<author><name sortKey="Kunisada, Yuki" sort="Kunisada, Yuki" uniqKey="Kunisada Y" first="Yuki" last="Kunisada">Yuki Kunisada</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan; Department of Oral and Maxillofacial Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan; Department of Oral and Maxillofacial Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558</wicri:regionArea>
<wicri:noRegion>Okayama 700-8558</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Eikawa, Shingo" sort="Eikawa, Shingo" uniqKey="Eikawa S" first="Shingo" last="Eikawa">Shingo Eikawa</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558</wicri:regionArea>
<wicri:noRegion>Okayama 700-8558</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tomonobu, Nahoko" sort="Tomonobu, Nahoko" uniqKey="Tomonobu N" first="Nahoko" last="Tomonobu">Nahoko Tomonobu</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558</wicri:regionArea>
<wicri:noRegion>Okayama 700-8558</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Domae, Shohei" sort="Domae, Shohei" uniqKey="Domae S" first="Shohei" last="Domae">Shohei Domae</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Oral and Maxillofacial Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Oral and Maxillofacial Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558</wicri:regionArea>
<wicri:noRegion>Okayama 700-8558</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Uehara, Takenori" sort="Uehara, Takenori" uniqKey="Uehara T" first="Takenori" last="Uehara">Takenori Uehara</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan; Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan; Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558</wicri:regionArea>
<wicri:noRegion>Okayama 700-8558</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hori, Shohei" sort="Hori, Shohei" uniqKey="Hori S" first="Shohei" last="Hori">Shohei Hori</name>
<affiliation wicri:level="4"><nlm:affiliation>Laboratory of Immunology and Microbiology, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo 113-0033, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Laboratory of Immunology and Microbiology, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo 113-0033</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
<orgName type="university">Université de Tokyo</orgName>
<placeName><settlement type="city">Tokyo</settlement>
<region type="province">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Furusawa, Yukihiro" sort="Furusawa, Yukihiro" uniqKey="Furusawa Y" first="Yukihiro" last="Furusawa">Yukihiro Furusawa</name>
<affiliation wicri:level="3"><nlm:affiliation>Division of Biochemistry, Keio University Graduate School of Pharmaceutical Science, Tokyo, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Division of Biochemistry, Keio University Graduate School of Pharmaceutical Science, Tokyo</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hase, Koji" sort="Hase, Koji" uniqKey="Hase K" first="Koji" last="Hase">Koji Hase</name>
<affiliation wicri:level="3"><nlm:affiliation>Division of Biochemistry, Keio University Graduate School of Pharmaceutical Science, Tokyo, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Division of Biochemistry, Keio University Graduate School of Pharmaceutical Science, Tokyo</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sasaki, Akira" sort="Sasaki, Akira" uniqKey="Sasaki A" first="Akira" last="Sasaki">Akira Sasaki</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Oral and Maxillofacial Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Oral and Maxillofacial Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558</wicri:regionArea>
<wicri:noRegion>Okayama 700-8558</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Udono, Heiichiro" sort="Udono, Heiichiro" uniqKey="Udono H" first="Heiichiro" last="Udono">Heiichiro Udono</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan. Electronic address: udono@cc.okayama-u.ac.jpudono@cc.okayama-u.ac.jp.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558</wicri:regionArea>
<wicri:noRegion>Okayama 700-8558</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">EBioMedicine</title>
<idno type="eISSN">2352-3964</idno>
<imprint><date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antigens, CD (genetics)</term>
<term>CTLA-4 Antigen (genetics)</term>
<term>Cell Differentiation (drug effects)</term>
<term>Forkhead Transcription Factors (genetics)</term>
<term>Gene Expression Regulation (drug effects)</term>
<term>Glucose Transporter Type 1 (genetics)</term>
<term>Humans (MeSH)</term>
<term>Integrin alpha Chains (genetics)</term>
<term>Interleukin-10 (genetics)</term>
<term>Lectins, C-Type (genetics)</term>
<term>Mechanistic Target of Rapamycin Complex 1 (antagonists & inhibitors)</term>
<term>Metformin (administration & dosage)</term>
<term>Neoplasms (drug therapy)</term>
<term>Neoplasms (genetics)</term>
<term>Neoplasms (pathology)</term>
<term>Protein Kinases (genetics)</term>
<term>Sirolimus (administration & dosage)</term>
<term>T-Lymphocytes, Regulatory (drug effects)</term>
<term>T-Lymphocytes, Regulatory (immunology)</term>
<term>Trans-Activators (genetics)</term>
<term>Tumor Microenvironment (drug effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Antigène CTLA-4 (génétique)</term>
<term>Antigènes CD (génétique)</term>
<term>Complexe-1 cible mécanistique de la rapamycine (antagonistes et inhibiteurs)</term>
<term>Différenciation cellulaire (effets des médicaments et des substances chimiques)</term>
<term>Facteurs de transcription Forkhead (génétique)</term>
<term>Humains (MeSH)</term>
<term>Interleukine-10 (génétique)</term>
<term>Intégrines alpha (génétique)</term>
<term>Lectines de type C (génétique)</term>
<term>Lymphocytes T régulateurs (effets des médicaments et des substances chimiques)</term>
<term>Lymphocytes T régulateurs (immunologie)</term>
<term>Metformine (administration et posologie)</term>
<term>Microenvironnement tumoral (effets des médicaments et des substances chimiques)</term>
<term>Protein kinases (génétique)</term>
<term>Régulation de l'expression des gènes (effets des médicaments et des substances chimiques)</term>
<term>Sirolimus (administration et posologie)</term>
<term>Transactivateurs (génétique)</term>
<term>Transporteur de glucose de type 1 (génétique)</term>
<term>Tumeurs (anatomopathologie)</term>
<term>Tumeurs (génétique)</term>
<term>Tumeurs (traitement médicamenteux)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Metformin</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Mechanistic Target of Rapamycin Complex 1</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Antigens, CD</term>
<term>CTLA-4 Antigen</term>
<term>Forkhead Transcription Factors</term>
<term>Glucose Transporter Type 1</term>
<term>Integrin alpha Chains</term>
<term>Interleukin-10</term>
<term>Lectins, C-Type</term>
<term>Protein Kinases</term>
<term>Trans-Activators</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Metformine</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Tumeurs</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Complexe-1 cible mécanistique de la rapamycine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Cell Differentiation</term>
<term>Gene Expression Regulation</term>
<term>T-Lymphocytes, Regulatory</term>
<term>Tumor Microenvironment</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Différenciation cellulaire</term>
<term>Lymphocytes T régulateurs</term>
<term>Microenvironnement tumoral</term>
<term>Régulation de l'expression des gènes</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Antigène CTLA-4</term>
<term>Antigènes CD</term>
<term>Facteurs de transcription Forkhead</term>
<term>Interleukine-10</term>
<term>Intégrines alpha</term>
<term>Lectines de type C</term>
<term>Protein kinases</term>
<term>Transactivateurs</term>
<term>Transporteur de glucose de type 1</term>
<term>Tumeurs</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Lymphocytes T régulateurs</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>T-Lymphocytes, Regulatory</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Humains</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">CD4<sup>+</sup>
CD25<sup>+</sup>
 regulatory T cells (Treg), an essential subset for preventing autoimmune diseases, is implicated as a negative regulator in anti-tumor immunity. We found that metformin (Met) reduced tumor-infiltrating Treg (Ti-Treg), particularly the terminally-differentiated CD103<sup>+</sup>
KLRG1<sup>+</sup>
 population, and also decreased effector molecules such as CTLA4 and IL-10. Met inhibits the differentiation of naïve CD4<sup>+</sup>
 T cells into inducible Treg (iTreg) by reducing forkhead box P3 (Foxp3) protein, caused by mTORC1 activation that was determined by the elevation of phosphorylated S6 (pS6), a downstream molecule of mTORC1. Rapamycin and compound C, an inhibitor of AMP-activated protein kinase (AMPK) restored the iTreg generation, further indicating the involvement of mTORC1 and AMPK. The metabolic profile of iTreg, increased Glut1-expression, and reduced mitochondrial membrane-potential and ROS production of Ti-Treg aided in identifying enhanced glycolysis upon Met-treatment. The negative impact of Met on Ti-Treg may help generation of the sustained antitumor immunity.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29066174</PMID>
<DateCompleted><Year>2018</Year>
<Month>07</Month>
<Day>09</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2352-3964</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>25</Volume>
<PubDate><Year>2017</Year>
<Month>Nov</Month>
</PubDate>
</JournalIssue>
<Title>EBioMedicine</Title>
<ISOAbbreviation>EBioMedicine</ISOAbbreviation>
</Journal>
<ArticleTitle>Attenuation of CD4<sup>+</sup>
CD25<sup>+</sup>
 Regulatory T Cells in the Tumor Microenvironment by Metformin, a Type 2 Diabetes Drug.</ArticleTitle>
<Pagination><MedlinePgn>154-164</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S2352-3964(17)30405-X</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ebiom.2017.10.009</ELocationID>
<Abstract><AbstractText>CD4<sup>+</sup>
CD25<sup>+</sup>
 regulatory T cells (Treg), an essential subset for preventing autoimmune diseases, is implicated as a negative regulator in anti-tumor immunity. We found that metformin (Met) reduced tumor-infiltrating Treg (Ti-Treg), particularly the terminally-differentiated CD103<sup>+</sup>
KLRG1<sup>+</sup>
 population, and also decreased effector molecules such as CTLA4 and IL-10. Met inhibits the differentiation of naïve CD4<sup>+</sup>
 T cells into inducible Treg (iTreg) by reducing forkhead box P3 (Foxp3) protein, caused by mTORC1 activation that was determined by the elevation of phosphorylated S6 (pS6), a downstream molecule of mTORC1. Rapamycin and compound C, an inhibitor of AMP-activated protein kinase (AMPK) restored the iTreg generation, further indicating the involvement of mTORC1 and AMPK. The metabolic profile of iTreg, increased Glut1-expression, and reduced mitochondrial membrane-potential and ROS production of Ti-Treg aided in identifying enhanced glycolysis upon Met-treatment. The negative impact of Met on Ti-Treg may help generation of the sustained antitumor immunity.</AbstractText>
<CopyrightInformation>Copyright © 2017 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kunisada</LastName>
<ForeName>Yuki</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan; Department of Oral and Maxillofacial Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Eikawa</LastName>
<ForeName>Shingo</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tomonobu</LastName>
<ForeName>Nahoko</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Domae</LastName>
<ForeName>Shohei</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Department of Oral and Maxillofacial Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Uehara</LastName>
<ForeName>Takenori</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan; Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hori</LastName>
<ForeName>Shohei</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Laboratory of Immunology and Microbiology, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo 113-0033, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Furusawa</LastName>
<ForeName>Yukihiro</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Division of Biochemistry, Keio University Graduate School of Pharmaceutical Science, Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hase</LastName>
<ForeName>Koji</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Division of Biochemistry, Keio University Graduate School of Pharmaceutical Science, Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sasaki</LastName>
<ForeName>Akira</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Oral and Maxillofacial Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Udono</LastName>
<ForeName>Heiichiro</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan. Electronic address: udono@cc.okayama-u.ac.jpudono@cc.okayama-u.ac.jp.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2017</Year>
<Month>10</Month>
<Day>16</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>EBioMedicine</MedlineTA>
<NlmUniqueID>101647039</NlmUniqueID>
<ISSNLinking>2352-3964</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015703">Antigens, CD</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D060908">CTLA-4 Antigen</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C556706">CTLA4 protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C418974">FOXP3 protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051858">Forkhead Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051272">Glucose Transporter Type 1</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D039001">Integrin alpha Chains</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C113413">KLRG1 protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D037181">Lectins, C-Type</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C495677">SLC2A1 protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015534">Trans-Activators</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C091367">alpha E integrins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>130068-27-8</RegistryNumber>
<NameOfSubstance UI="D016753">Interleukin-10</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>9100L32L2N</RegistryNumber>
<NameOfSubstance UI="D008687">Metformin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.-</RegistryNumber>
<NameOfSubstance UI="D011494">Protein Kinases</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.1.-</RegistryNumber>
<NameOfSubstance UI="C086028">AMP-activated protein kinase kinase</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D000076222">Mechanistic Target of Rapamycin Complex 1</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>W36ZG6FT64</RegistryNumber>
<NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D015703" MajorTopicYN="N">Antigens, CD</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D060908" MajorTopicYN="N">CTLA-4 Antigen</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051858" MajorTopicYN="N">Forkhead Transcription Factors</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051272" MajorTopicYN="N">Glucose Transporter Type 1</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D039001" MajorTopicYN="N">Integrin alpha Chains</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016753" MajorTopicYN="N">Interleukin-10</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D037181" MajorTopicYN="N">Lectins, C-Type</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000076222" MajorTopicYN="N">Mechanistic Target of Rapamycin Complex 1</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008687" MajorTopicYN="N">Metformin</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011494" MajorTopicYN="N">Protein Kinases</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D050378" MajorTopicYN="N">T-Lymphocytes, Regulatory</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015534" MajorTopicYN="N">Trans-Activators</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Glycolysis</Keyword>
<Keyword MajorTopicYN="N">Regulatory T cell (Treg)</Keyword>
<Keyword MajorTopicYN="N">Tumor immunity</Keyword>
<Keyword MajorTopicYN="N">Tumor microenvironment</Keyword>
<Keyword MajorTopicYN="N">mTOR</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year>
<Month>04</Month>
<Day>19</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2017</Year>
<Month>10</Month>
<Day>04</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2017</Year>
<Month>10</Month>
<Day>09</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2017</Year>
<Month>10</Month>
<Day>27</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2018</Year>
<Month>7</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2017</Year>
<Month>10</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">29066174</ArticleId>
<ArticleId IdType="pii">S2352-3964(17)30405-X</ArticleId>
<ArticleId IdType="doi">10.1016/j.ebiom.2017.10.009</ArticleId>
<ArticleId IdType="pmc">PMC5704053</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Nature. 2013 Dec 19;504(7480):446-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24226770</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Trends Immunol. 2015 Jan;36(1):3-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25248463</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunity. 2012 Feb 24;36(2):262-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22326580</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Cancer Res. 2013 Oct 1;19(19):5372-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23942093</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 2015 Jan;125(1):194-207</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25437876</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Cancer. 2010 Aug 15;127(4):759-67</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20518016</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Exp Med. 2005 Oct 3;202(7):919-29</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16186184</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunity. 2015 Sep 15;43(3):579-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26341400</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Immunol. 2003 Apr;4(4):330-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12612578</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Endocr Relat Cancer. 2006 Jun;13(2):273-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16728563</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nucleic Acids Res. 2013 Jan 7;41(1):e1</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22933715</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Res. 2012 May 1;72(9):2162-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22549946</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2007 Mar 1;178(5):2883-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17312132</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Cell. 2008 Apr 25;30(2):214-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18439900</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Rep. 2015 Aug 28;5:13548</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26315217</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Metab. 2017 Jun 6;25(6):1282-1293.e7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28416194</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2003 Oct 9;425(6958):577-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14534577</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2011 Jan 21;331(6015):337-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21205640</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Gynecol Oncol. 2012 Nov;127(2):390-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22864111</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Biol Ther. 2015;16(1):77-87</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25456211</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Immunol Res. 2017 Jan;5(1):9-16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27941003</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2013 Nov 22;342(6161):967-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24264989</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 1999 Nov 15;163(10):5211-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10553041</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2015 Dec 10;528(7581):262-266</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26633628</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Rep. 2012;2:362</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22500211</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Res. 2009 Oct 1;69(19):7507-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19752085</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2003 Feb 14;299(5609):1057-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12522256</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunity. 2010 Feb 26;32(2):266-78</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20137985</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):E2950-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23878245</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2011 Mar 15;186(6):3299-303</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21317389</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>In Vivo. 2012 Jul-Aug;26(4):519-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22773563</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Annu Rev Med. 2015;66:17-29</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25386929</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Res. 1999 Jul 1;59(13):3128-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10397255</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16344461</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2012;7(3):e33411</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22448244</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2005 Jun 4;330(7503):1304-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15849206</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Immunol. 2016 Feb;16(2):102-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26781939</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):1809-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25624476</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Immunol. 2015 Aug;16(8):871-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26147684</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Front Immunol. 2013 Jul 11;4:190</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23874336</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Cancer Res. 2015 Oct 1;21(19):4327-36</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26429981</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2012 Aug 15;189(4):1780-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22786769</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2014 Oct 3;289(40):27692-701</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25143389</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Prev Res (Phila). 2010 Sep;3(9):1066-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20810672</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2013 Nov 22;342(6161):971-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24264990</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Japon</li>
</country>
<region><li>Région de Kantō</li>
</region>
<settlement><li>Tokyo</li>
</settlement>
<orgName><li>Université de Tokyo</li>
</orgName>
</list>
<tree><country name="Japon"><noRegion><name sortKey="Kunisada, Yuki" sort="Kunisada, Yuki" uniqKey="Kunisada Y" first="Yuki" last="Kunisada">Yuki Kunisada</name>
</noRegion>
<name sortKey="Domae, Shohei" sort="Domae, Shohei" uniqKey="Domae S" first="Shohei" last="Domae">Shohei Domae</name>
<name sortKey="Eikawa, Shingo" sort="Eikawa, Shingo" uniqKey="Eikawa S" first="Shingo" last="Eikawa">Shingo Eikawa</name>
<name sortKey="Furusawa, Yukihiro" sort="Furusawa, Yukihiro" uniqKey="Furusawa Y" first="Yukihiro" last="Furusawa">Yukihiro Furusawa</name>
<name sortKey="Hase, Koji" sort="Hase, Koji" uniqKey="Hase K" first="Koji" last="Hase">Koji Hase</name>
<name sortKey="Hori, Shohei" sort="Hori, Shohei" uniqKey="Hori S" first="Shohei" last="Hori">Shohei Hori</name>
<name sortKey="Sasaki, Akira" sort="Sasaki, Akira" uniqKey="Sasaki A" first="Akira" last="Sasaki">Akira Sasaki</name>
<name sortKey="Tomonobu, Nahoko" sort="Tomonobu, Nahoko" uniqKey="Tomonobu N" first="Nahoko" last="Tomonobu">Nahoko Tomonobu</name>
<name sortKey="Udono, Heiichiro" sort="Udono, Heiichiro" uniqKey="Udono H" first="Heiichiro" last="Udono">Heiichiro Udono</name>
<name sortKey="Uehara, Takenori" sort="Uehara, Takenori" uniqKey="Uehara T" first="Takenori" last="Uehara">Takenori Uehara</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000918 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000918 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    RapamycinFungusV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:29066174
   |texte=   Attenuation of CD4+CD25+ Regulatory T Cells in the Tumor Microenvironment by Metformin, a Type 2 Diabetes Drug.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:29066174" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a RapamycinFungusV1

This area was generated with Dilib version V0.6.38.
Data generation: Thu Nov 19 21:55:41 2020. Site generation: Thu Nov 19 22:00:39 2020

	Serveur d'exploration sur la rapamycine et les champignons
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la rapamycine et les champignons

Attenuation of CD4+CD25+ Regulatory T Cells in the Tumor Microenvironment by Metformin, a Type 2 Diabetes Drug.

Attenuation of CD4+CD25+ Regulatory T Cells in the Tumor Microenvironment by Metformin, a Type 2 Diabetes Drug.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki